Safeway Secures 200,000 Additional Doses of Flu Vaccine to Meet High Demand

Wed Jan 16, 2013 2:19pm EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link

PLEASANTON, Calif.,  Jan. 16, 2013  /PRNewswire/ -- Safeway Inc. (NYSE: SWY)
announced today it has shipped an additional 200,000 doses of flu vaccine to its
pharmacies in the U.S. to be administered to customers on site.  

"This additional quantity of flu vaccine will allow us to meet the needs of our
customers to help them remain healthy this season," said  Darren Singer, Senior
Vice President of Pharmacy. "Our pharmacists administer the vaccine on a walk-in
basis. The process is simple, convenient and affordable. We want all of our
customers to have this protection."

According to the Centers for Disease Control, 47 states are reporting widespread
flu activity with infection numbers making this the worst flu season in a
decade. The vaccine remains the best protection against the flu.    

To encourage customers to receive a flu vaccine and promote health and wellness,
Safeway is giving each customer who receives a flu vaccine at a Safeway Pharmacy
a coupon for 10 percent off their next grocery purchase.  

Vaccines are conveniently available at all Safeway Pharmacy locations during
normal business hours, seven days a week, on a walk-in basis. No appointments
are required and no prescription is necessary. For more information on stores
offering the flu vaccine, customers can contact their local Safeway store.

About Safeway

Safeway Inc. is a Fortune 100 company and one of the largest food and drug
retailers in  North America, based on sales. The company operates 1,644 stores
in  the United States  and western  Canada  and had annual sales of  $43.6
billion  in 2011. The company's common stock is traded on the New York Stock
Exchange under the symbol SWY. For more information, visit

 Contact:  Teena Massingill, 925-467-3810  

SOURCE  Safeway Inc.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.